TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32080310

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 21
Study: 35260901

Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL) Teenage Pregnancy Prevention program
Number of subjects: 518
Study: 33089669

Group type: EXPERIMENTAL
Intervention: Voiding disorders (identified using the DVISS scale with a score of 8.5 or above)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Day-time urinary incontinence
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Night-time incontinence
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Family history of voiding disorders
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 907
Study: 35213246

Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34598983

Group type: EXPERIMENTAL
Intervention: Recorded music through overear headphones before, during, and after surgery until postoperative day 3.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical care (control group).
Number of subjects: 0
Study: 35279338

Group type: EXPERIMENTAL
Intervention: Custom group (alternative drugs based on pharmacogenetic testing)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (oxycodone, tramadol, and celecoxib)
Number of subjects: 107
Study: 35639969

Group type: EXPERIMENTAL
Intervention: PSI-Motivate scores
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: PSI-Barrier subscores
Number of subjects: 371
Study: 34452970

Group type: EXPERIMENTAL
Intervention: CORKA (Community Rehabilitation after Knee Arthroplasty) home‐based rehabilitation, receiving a median five treatment sessions (IQR 4‐7)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy, receiving a median 4 sessions (IQR 2‐6)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: CORKA home‐based rehabilitation
Number of subjects: 621

Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy
Number of subjects: 621
Study: 32516395

Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinpro White Varnish
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shield Force Plus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 40
Study: 36327275

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous butylscopolamine bromide
Number of subjects: 250

Group type: COMPARATOR
Intervention: Intravenous placebo (1 mL sodium chlorine 9 mg/mL)
Number of subjects: 250
Study: 32634291

Group type: EXPERIMENTAL
Intervention: Sleep apnoea
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Restless legs
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Nightmares
Number of subjects: 276
Study: 32125929

Group type: EXPERIMENTAL
Intervention: ATRIPLA + rosemary aqueous extract (4 g/L per day)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ATRIPLA + rosemary methanolic extract (400 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: ATRIPLA
Number of subjects: 67
Study: 35245297

Group type: EXPERIMENTAL
Intervention: Reinforcement healthcare workers deployed to ICUs
Number of subjects: 30
Study: 32667151

Group type: EXPERIMENTAL
Intervention: Collagen-based treatment combined with proprioceptive neuromuscular facilitation protocol (Kabat method) (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation protocol (Kabat method) only (Group B)
Number of subjects: 41
Study: 35198794

Group type: EXPERIMENTAL
Intervention: Mobile application with coaching for 6 weeks
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group with pre-existing nutritionist support
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Mobile application and additional coaching in the SMART trial
Number of subjects: 900
Study: 32208397

Group type: EXPERIMENTAL
Intervention: Prasugrel 3.75 mg (PRA3.75)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg (PRA2.5)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Clopidogrel 50 mg (CLO50)
Number of subjects: 654
Study: 34872404

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33135443

Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted bi-unicompartmental knee arthroplasty (bi-UKA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 70
Study: 36494113

Group type: EXPERIMENTAL
Intervention: BiominF slurry and toothpaste (Bio-BAG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Novamin slurry and toothpaste (N-BAG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recaldent paste (CPP-ACP)
Number of subjects: 60
Study: 33906526

Group type: EXPERIMENTAL
Intervention: Nitrate-based nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid) administered every 4 hours during a 48-hour monitoring period.
Number of subjects: 5
Study: 32737482

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 156

Group type: COMPARATOR
Intervention: Boosted PIs
Number of subjects: 156
Study: 35905752

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South Africa or 300 mg lamivudine in Uganda)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Efavirenz-based regimen (fixed dose combination 600 mg tenofovir disoproxil fumarate plus either emtricitabine in South Africa or lamivudine in Uganda)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 268

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Infants in both groups
Number of subjects: 268
Study: 33795488

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 33358601

Group type: EXPERIMENTAL
Intervention: Breath-hold during prone positioning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Free breathing
Number of subjects: 15
Study: 36116413

Group type: EXPERIMENTAL
Intervention: MP2/cc‐pVTZ method to calculate the Raman spectra of serine conformers
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Statistical analysis of local coupling in serine methylene
Number of subjects: 85
Study: 34384509

Group type: EXPERIMENTAL
Intervention: Moral message with content referring to ethical virtue
Number of subjects: 3662

Group type: EXPERIMENTAL
Intervention: Deontological and utilitarian messages
Number of subjects: 3662

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 3662
Study: 32926799

Group type: EXPERIMENTAL
Intervention: Curcuma longa extract (CL) 2 capsules per day for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matched placebo 2 capsules per day for 12 weeks
Number of subjects: 70
Study: 36137689

Group type: EXPERIMENTAL
Intervention: Ultrathin bioresorbable polymer sirolimus-eluting stents (BP SES)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Thin durable polymer everolimus-eluting stents (DP EES)
Number of subjects: 1334
Study: 35614473

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg codeine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg codeine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg codeine
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0.2 mg/kg morphine (positive control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All codeine dose groups
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 7
Study: 34875345

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CCFM1025 (10^10 CFU daily for 4 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CCFM1025
Number of subjects: 45
Study: 34688319

Group type: EXPERIMENTAL
Intervention: nHA prosthesis based on CT‐scanning data
Number of subjects: 26

Group type: COMPARATOR
Intervention: titanium mesh
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: nHA prosthesis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: nHA prosthesis and titanium mesh
Number of subjects: 26
Study: 35147093

Group type: EXPERIMENTAL
Intervention: MI retention counseling and telephonic tracing
Number of subjects: 711

Group type: COMPARATOR
Intervention: biannual telephonic tracing
Number of subjects: 711

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 711
Study: 34201328

Group type: COMPARATOR
Intervention: Gutta-percha (GP) for obturation (control group, n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) for obturation (n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gutta-percha (GP) for obturation + grafting procedure (n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) for obturation + grafting procedure (n = 30)
Number of subjects: 120
Study: 36270978

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 144
Study: 34765813

Group type: EXPERIMENTAL
Intervention: Anterior subconjunctival anesthesia (ASCA)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sub-tenon's anesthesia (STA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ASCA
Number of subjects: 164

Group type: COMPARATOR
Intervention: STA
Number of subjects: 164
Study: 35551091

Group type: EXPERIMENTAL
Intervention: Goal-directed mobilisation (GDM) intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 160
Study: 36180132

Group type: EXPERIMENTAL
Intervention: 25(OH)D <20.0 ng/mL
Number of subjects: 152

Group type: COMPARATOR
Intervention: 25(OH)D sufficient
Number of subjects: 152
Study: 34156906

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided imagery and reflexology
Number of subjects: 0
Study: 33142510

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/kg) supplementation during the grower phase (11-24 d)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin E and omega-3 fatty acids during the starter phase (0-10 d)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (corn-soybean meal basal diet)
Number of subjects: 210
Study: 34225541

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg)/Daclatasvir (60 mg) for 14 days with conventional therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 174
Study: 32460584

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Yoga (MB yoga), n=41, weekly classes and independent practice
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group, n=39, no yoga intervention
Number of subjects: 80
Study: 33046214

Group type: EXPERIMENTAL
Intervention: Statin therapy (represented by variants in the HMGCR gene region)
Number of subjects: 367703

Group type: COMPARATOR
Intervention: Alternative lipid-lowering treatments (PCSK9, LDLR, NPC1L1, APOC3, LPL)
Number of subjects: 367703

Group type: COMPARATOR
Intervention: Genetically predicted LDL-cholesterol
Number of subjects: 367703
Study: 616869714

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colistimethate sodium (COLI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment Satisfaction (TIP)
Number of subjects: 60
Study: 35466498

Group type: EXPERIMENTAL
Intervention: Bar group: overdentures connected to implants with bar/clip attachments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Telescopic group: overdentures connected to implants using a resilient telescopic attachment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stud group: overdentures connected to implants with resilient stud (Locator) attachments
Number of subjects: 90
Study: 33792646

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy in KEYNOTE-059
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy in KEYNOTE-061
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel) in KEYNOTE-061
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy in KEYNOTE-062
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in KEYNOTE-062
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Chemotherapy alone in KEYNOTE-062
Number of subjects: 1370
Study: 35224778

Group type: EXPERIMENTAL
Intervention: Porcine bone mineral mixed with autogenous bone graft (20:80 ratio)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone mixed with autogenous bone graft (20:80 ratio)
Number of subjects: 10
Study: 32147197

Group type: EXPERIMENTAL
Intervention: Vegan diet (VD)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Meat-rich diet (MD)
Number of subjects: 53
Study: 36319059

Group type: EXPERIMENTAL
Intervention: 12-week digitally distributed yoga intervention, practicing yoga two times a week (one live-streamed class and one prerecorded video class for self-training)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standardised care, gift cards for flowers, and access to yoga video links after data collection
Number of subjects: 240
Study: 32145701

Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FM) 500 mg IV alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FM) 500 mg IV followed by phenylbutazone (PBZ) 2 g IV 24 hours later
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (Flunixin meglumine alone)
Number of subjects: 12
Study: 36495036

Group type: EXPERIMENTAL
Intervention: CSPCHA115 (25-1000 mg) in SAD study
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CSPCHA115 (100, 200, 400, or 600 mg) in MAD study
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CSPCHA115 (single and multiple doses)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CSPCHA115
Number of subjects: 88
Study: 33890156

Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 86

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 86
Study: 32513895

Group type: EXPERIMENTAL
Intervention: Discharged with a tracheostomy
Number of subjects: 622

Group type: COMPARATOR
Intervention: Remained in ICU until tracheostomy removal or death
Number of subjects: 622
Study: 33751764

Group type: EXPERIMENTAL
Intervention: Guided dose reduction (GDR) - patients reduce no more than 25% of their baseline antipsychotic dose, with a 6-month stabilization period before further reduction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance treatment group (MTG1) - patients continue their current antipsychotic treatment without reduction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturalistic maintenance controls (MTG2) - eligible patients who do not intend to reduce antipsychotics.
Number of subjects: 0
Study: 32921569

Group type: EXPERIMENTAL
Intervention: Pain medication (used by 166 out of 299 patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Pain (experienced by 108 individuals)
Number of subjects: 299
Study: 34129409

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 51

Group type: COMPARATOR
Intervention: Polyglactin sutures
Number of subjects: 51
Study: 33094909

Group type: EXPERIMENTAL
Intervention: Cardiopoietic stem cells delivered intramyocardially using a retention-enhanced catheter
Number of subjects: 315

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 315
Study: 36183748

Group type: EXPERIMENTAL
Intervention: St Jude Epic bioprosthesis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups with larger prostheses (23 mm or more)
Number of subjects: 300
Study: 32546384

Group type: EXPERIMENTAL
Intervention: 15 minutes titration of intravenous oxytocin post birth
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 30 minutes titration of intravenous oxytocin post birth
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 60 minutes titration of intravenous oxytocin post birth
Number of subjects: 365
Study: 32955177

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study: 35987527

Group type: EXPERIMENTAL
Intervention: Guided online self-navigation
Number of subjects: 307

Group type: COMPARATOR
Intervention: In-person assistance
Number of subjects: 307
Study: 34688283

Group type: EXPERIMENTAL
Intervention: EYE-2 intervention plus standardised EIP service
Number of subjects: 950

Group type: COMPARATOR
Intervention: Standardised EIP service alone
Number of subjects: 950
Study: 32791973

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside with pterostilbene (NRPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34856023

Group type: EXPERIMENTAL
Intervention: Healthy Beginnings intervention delivered via telephone calls and text messages
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Healthy Beginnings intervention
Number of subjects: 20
Study: 32962480

Group type: EXPERIMENTAL
Intervention: Biocage
Number of subjects: 67

Group type: COMPARATOR
Intervention: PEEK
Number of subjects: 67
Study: 34937036

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (GDS ≥4)
Number of subjects: 309
Study: 32900535

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi) 7 U
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi) 15 U
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi) 30 U
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lispro (Humalog®) 7 U
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lispro (Humalog®) 15 U
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lispro (Humalog®) 30 U
Number of subjects: 42
Study: 34406535

Group type: EXPERIMENTAL
Intervention: Early exercise group (E‐EG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Late exercise group (L‐EG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 88
Study: 33531075

Group type: EXPERIMENTAL
Intervention: Guadecitabine + GVAX (granulocyte macrophage‐colony‐stimulating‐factor secreting colon cancer vaccine)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Guadecitabine + GVAX
Number of subjects: 18
Study: 34270379

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg once daily p.o. for eight days starting on the day of HCG administration)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Calcium gluconate (10%, 10 ml in 200 ml of physiologic saline, administered daily for four days starting on the day of ovum pickup)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 170

Group type: COMPARATOR
Intervention: Calcium gluconate
Number of subjects: 170
Study: 33485600

Group type: EXPERIMENTAL
Intervention: CHW-based educational intervention
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard clinical care (Control)
Number of subjects: 234
Study: 35701842

Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy for insomnia (CBT‐i) for 6 weeks, using Sleepio, an online interactive program with six sessions, once a week.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Educational program (control) for 6 weeks, consisting of six emails with general sleep information, once a week.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy for insomnia (CBT‐i)
Number of subjects: 98
Study: 36115790

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs) plus standard physiotherapy (SP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Identical-looking placebos plus standard physiotherapy (SP)
Number of subjects: 60
Study: 36301862

Group type: EXPERIMENTAL
Intervention: Nutrient bar supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 35954677

Group type: EXPERIMENTAL
Intervention: Group music intervention (20 sessions, two 30-min sessions per week for 10 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care (control group, no music intervention)
Number of subjects: 63
Study: 33230059

Group type: COMPARATOR
Intervention: famotidine (20 mg bid)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: omeprazole (20 mg qd)
Number of subjects: 170
Study: 34569408

Group type: EXPERIMENTAL
Intervention: Single-inhaler triple therapy for COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive selection trial design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: De-escalation from inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment escalation studies
Number of subjects: 0
Study: 32865102

Group type: EXPERIMENTAL
Intervention: Urinary habit training during hospital stay with telephonic reinforcement 10 days after discharge
Number of subjects: 109

Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 109
Study: 32067262

Group type: EXPERIMENTAL
Intervention: ACT-539313 100 mg in fasted conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT-539313 100 mg in fed conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT-539313 (various doses 10-400 mg)
Number of subjects: 40
Study: 35051949

Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Crisis Counseling (CC)
Number of subjects: 239
Study: 33645911

Group type: EXPERIMENTAL
Intervention: Linked colour imaging
Number of subjects: 302

Group type: COMPARATOR
Intervention: White-light colonoscopy
Number of subjects: 302
Study: 35388321

Group type: EXPERIMENTAL
Intervention: SIMV-PSV-PEEP + AutoFlow
Number of subjects: 100

Group type: COMPARATOR
Intervention: SIMV-PSV-PEEP
Number of subjects: 100